(Q55461270)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24429479%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

title

Low-dose fractionated radiotherapy and concomitant chemotherapy for recurrent or progressive glioblastoma: final report of a pilot study (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24429479%20AND%20SRC:MED&resulttype=core&format=json

Adaptive radiation therapy

5 March 2020

main subject

0 references

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24429479%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Silvia Chiesa

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24429479%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Vincenzo Valentini

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24429479%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

8

G Maira

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24429479%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

author name string

M Balducci

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24429479%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

G R D'Agostino

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24429479%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

M A Gambacorta

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24429479%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

M Ferro

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24429479%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

C Colosimo

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24429479%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

C Anile

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24429479%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

publication date

17 January 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24429479%20AND%20SRC:MED&resulttype=core&format=json

Strahlentherapie und Onkologie

5 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24429479%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

volume

190

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24429479%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24429479%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

page(s)

370-376

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24429479%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s00066-013-0506-z

5 March 2020

exact match

0 references

cites work

Prolonged survival when temozolomide is added to accelerated radiotherapy for glioblastoma multiforme.

1 reference

https://api.crossref.org/works/10.1007%2FS00066-013-0506-Z

Radiotherapy of glioblastoma multiforme. Feasibility of increased fraction size and shortened overall treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00066-013-0506-Z

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00066-013-0506-Z

Target volumes in radiotherapy for high-grade malignant glioma of the brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00066-013-0506-Z

Patterns of failure following treatment for glioblastoma multiforme and anaplastic astrocytoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00066-013-0506-Z

Bevacizumab plus irinotecan in recurrent glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00066-013-0506-Z

CT-guided interstitial HDR brachytherapy for recurrent glioblastoma multiforme. Long-term results.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00066-013-0506-Z

Hypofractionated reirradiation for recurrent malignant glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00066-013-0506-Z

Hypofractionated stereotactic reirradiation of recurrent glioblastomas : a beneficial treatment option after high-dose radiotherapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00066-013-0506-Z

Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00066-013-0506-Z

Therapeutic options for recurrent malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00066-013-0506-Z

Temozolomide rechallenge in recurrent malignant glioma by using a continuous temozolomide schedule: the "rescue" approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00066-013-0506-Z

The response of human glioma cell lines to low-dose radiation exposure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00066-013-0506-Z

Low dose hypersensitivity in the T98G human glioblastoma cell line.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00066-013-0506-Z

Human malignant glioma cell lines are sensitive to low radiation doses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00066-013-0506-Z

Low-dose hyperradiosensitivity of human glioblastoma cell lines in vitro does not translate into improved outcome of ultrafractionated radiotherapy in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00066-013-0506-Z

Low-dose hypersensitivity after fractionated low-dose irradiation in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00066-013-0506-Z

Recurrent glioblastoma multiforme: advances in treatment and promising drug candidates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00066-013-0506-Z

Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00066-013-0506-Z

Salvage temozolomide for prior temozolomide responders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00066-013-0506-Z

Comparative diffusion study of two nitrosoureas: carmustine and fotemustine in normal rat brain, human and rat brain biopsies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00066-013-0506-Z

A multi-institutional phase II study on second-line Fotemustine chemotherapy in recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00066-013-0506-Z

Second-line chemotherapy with fotemustine in temozolomide-pretreated patients with relapsing glioblastoma: a single institution experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00066-013-0506-Z

Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00066-013-0506-Z

Radiation dose-volume effects in the brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00066-013-0506-Z

Radiotherapy and concomitant temozolomide during the first and last weeks in high grade gliomas: long-term analysis of a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00066-013-0506-Z

The effect of very low radiation doses on the human bladder carcinoma cell line RT112.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00066-013-0506-Z

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00066-013-0506-Z

Intrinsic radiation sensitivity may not be the major determinant of the poor clinical outcome of glioblastoma multiforme.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00066-013-0506-Z

DNA repair and cancer stem-like cells--potential partners in glioma drug resistance?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00066-013-0506-Z

p53-dependent apoptosis modulates the cytotoxicity of anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00066-013-0506-Z

Defective p53 antiangiogenic signaling in glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00066-013-0506-Z

Therapeutic options for recurrent high-grade glioma in adult patients: recent advances

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00066-013-0506-Z

Treatment options for recurrent glioblastoma: pitfalls and future trends

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00066-013-0506-Z

Carmustine wafers: localized delivery of chemotherapeutic agents in CNS malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00066-013-0506-Z

Use of Gliadel (BCNU) wafer in the surgical treatment of malignant glioma: a 10-year institutional experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00066-013-0506-Z

Recurrent glioblastoma: a fresh look at current therapies and emerging novel approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00066-013-0506-Z

Low-dose hyper-radiosensitivity: a consequence of ineffective cell cycle arrest of radiation-damaged G2-phase cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00066-013-0506-Z

Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00066-013-0506-Z

Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00066-013-0506-Z

A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00066-013-0506-Z

One week on/one week off: a novel active regimen of temozolomide for recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00066-013-0506-Z

Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00066-013-0506-Z

The use of 'top-up' experiments to investigate the effect of very small doses per fraction in mouse skin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00066-013-0506-Z

A low-dose hypersensitive keratinocyte loss in response to fractionated radiotherapy is associated with growth arrest and apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00066-013-0506-Z

Sensing radiosensitivity of human epidermal stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00066-013-0506-Z

Effects of cell cycle phase on low-dose hyper-radiosensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00066-013-0506-Z

Prolonged survival for patients with newly diagnosed, inoperable glioblastoma with 3-times daily ultrafractionated radiation therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00066-013-0506-Z

Low-dose hyperradiosensitivity: is there a place for future investigation in clinical settings?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00066-013-0506-Z

Low-dose fractionated radiotherapy and concomitant chemotherapy in glioblastoma multiforme with poor prognosis: a feasibility study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00066-013-0506-Z

High doses per fraction and the linear-quadratic model

21 January 2018

1 reference

12 December 2020

Low-dose radiation hypersensitivity is associated with p53-dependent apoptosis.

1 reference

12 December 2020

Low dose fractionated radiation potentiates the effects of taxotere in nude mice xenografts of squamous cell carcinoma of head and neck.

1 reference

12 December 2020

Response criteria for phase II studies of supratentorial malignant glioma

1 reference

12 December 2020

Low-dose fractionated radiation as a chemopotentiator of neoadjuvant paclitaxel and carboplatin for locally advanced squamous cell carcinoma of the head and neck: results of a new treatment paradigm

1 reference

12 December 2020

Chemotherapeutic wafers for High Grade Glioma

1 reference

12 December 2020

Low-dose radiotherapy as a chemo-potentiator of a chemotherapy regimen with pemetrexed for recurrent non-small-cell lung cancer: A prospective phase II study

1 reference

12 December 2020

In vitro chemosensitivity testing of Fotemustine (S 10036), a new antitumor nitrosourea

1 reference

12 December 2020

Low-dose radiotherapy as a chemopotentiator of gemcitabine in tumors of the pancreas or small bowel: a phase I study exploring a new treatment paradigm

1 reference

12 December 2020

Practical guidelines for the treatment of malignant gliomas.

1 reference

12 December 2020

Tolerance of normal tissue to therapeutic irradiation

1 reference

12 December 2020

Renal Damage in the Mouse: The Response to Very Small Doses per Fraction

1 reference

12 December 2020

Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials

1 reference

12 December 2020

Low dose fractionated radiation enhances the radiosensitization effect of paclitaxel in colorectal tumor cells with mutant p53

1 reference

12 December 2020

Low-dose fractionated radiation potentiates the effects of Paclitaxel in wild-type and mutant p53 head and neck tumor cell lines

1 reference

12 December 2020